Annals of Epidemiology
Volume 21, Issue 1 , Pages 1-14 , January 2011

Hemochromatosis Genotypes and Risk of Iron Overload—A Meta-Analysis

  • Adriana Maria Neghina, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Adriana Maria Neghina, MD, Victor Babes University of Medicine and Pharmacy, Biochemistry Department, 2 Eftimie Murgu Square, 300041 Timisoara, Romania. Tel.: +0040-721-046-386.
    • ,
  • Andrei Anghel, PhD

Received 19 January 2010 ,Accepted 24 May 2010.

References 

  1. Griffiths WJ. Review article: the genetic basis of hemochromatosis. Aliment Pharmacol Ther. 2007;26:331–342
  2. McLaren CE, Li KT, McLaren GD, Gordeuk VR, Snively BM, Reboussin DM, et al. Mixture models of serum iron measures in population screening for hemochromatosis and iron overload. Transl Res. 2006;148:196–206
  3. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006;145:209–223
  4. Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, Watson N, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci U S A. 1998;95:1472–1477
  5. Whittington C. Genetics of hereditary hemochromatosis. BC Med J. 2002;44:544–546
  6. Beutler E. The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clinical hereditary hemochromatosis. Blood. 2003;101:3347–3350
  7. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001;154:193–206
  8. de Juan D, Reta A, Castiella A, Pozueta J, Prada A, Cuadrado E. HFE gene mutations analysis in Basque hereditary hemochromatosis patients and controls. Eur J Hum Genet. 2001;9:961–964
  9. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta. 1996;245:139–200
  10. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA. 1998;280:172–178
  11. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis. A public health perspective. Am J Prev Med. 1999;16:134–140
  12. McCullen MA, Crawford DH, Hickman PE. Screening for hemochromatosis. Clin Chim Acta. 2002;315:169–186
  13. The Nordic Cochrane Centre. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen. 2008.
  14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  15. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  17. Egger M, Schneider M, Davey SG. Spurious precision? Meta-analysis of observational studies. BMJ. 1998;316:140–144
  18. McDonnell SM, Hover A, Gloe D, Ou CY, Cogswell ME, Grummer-Strawn L. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med. 1999;107:30–37
  19. Burt MJ, George PM, Upton JD, et al. The significance of hemochromatosis gene mutations in the general population: implications for screening. Gut. 1998;43:830–836
  20. Holmstrom P, Marmur J, Eggertsen G, Gafvels M, Stal P. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut. 2002;51:723–730
  21. Simsek H, Sumer H, Yilmaz E, et al. Frequency of HFE mutations among Turkish blood donors according to transferrin saturation: genotype screening for hereditary hemochromatosis among voluntary blood donors in Turkey. J Clin Gastroenterol. 2004;38:671–675
  22. Baptista-Gonzalez HA, Rosenfeld-Mann F, Trueba-Gomez R, Bermejo-Martinez L, Mendez-Sanchez N. Association of HFE mutations (C282Y and H63D) with iron overload in blood donors from Mexico City. Ann Hepatol. 2007;6:55–60
  23. Vizzi E, Loureiro CL, Gerder M, de las Nieves Garcia-Casal M, Rodríguez-Larralde A, Gerace L, et al. Mutation analysis of the HFE gene associated with hereditary hemochromatosis in a Venezuelan sample. Ann Hematol. 2005;84:802–806
  24. Salvioni A, Mariani R, Oberkanins C, Moritz A, Mauri V, Pelucchi S, et al. Prevalence of C282Y and E168X HFE mutations in an Italian population of Northern European ancestry. Haematologica. 2003;88:250–255
  25. Tuomainen TP, Kontula K, Nyyssonen K, Lakka TA, Helio T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in eastern Finland. Circulation. 1999;100:1274–1279
  26. de Diego C, Murga MJ, Martinez-Castro P. Frequency of HFE H63D, S65C, and C282Y mutations in patients with iron overload and controls from Toledo, Spain. Genet Test. 2004;8:263–267
  27. Kingston J, Bowen D, Sweeney M, Lawless S, Jackson H, Worwood M. Heteroduplex analysis for the three common HFE variants: methodology, reliability and analysis of over 5000 requests for testing. J Clin Pathol. 2007;60:1244–1248
  28. Mura C, Nousbaum JB, Verger P, Moalic MT, Raguenes O, Mercier AY, et al. Phenotype-genotype correlation in hemochromatosis subjects. Hum Genet. 1997;101:271–276
  29. Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood. 1999;93:2502–2505
  30. Vantyghem MC, Fajardy I, Dhondt F, Girardot C, D'Herbomez M, Danze PM, et al. Phenotype and HFE genotype in a population with abnormal iron markers recruited from an Endocrinology Department. Eur J Endocrinol. 2006;154:835–841
  31. Guix P, Picornell A, Parera M, Galmes A, Obrador A, Ramon MM, et al. Distribution of HFE C282Y and H63D mutations in the Balearic Islands (NE Spain). Clin Genet. 2002;61:43–48
  32. Hellerbrand C, Bosserhoff AK, Seegers S, Lingner G, Wrede C, Lock G, et al. Mutation analysis of the HFE gene in German hemochromatosis patients and controls using automated SSCP-based capillary electrophoresis and a new PCR-ELISA technique. Scand J Gastroenterol. 2001;36:1211–1216
  33. Papanikolaou G, Politou M, Terpos E, Fourlemadis S, Sakellaropoulos N, Loukopoulos D. Hereditary hemochromatosis: HFE mutation analysis in Greeks reveals genetic heterogeneity. Blood Cells Mol Dis. 2000;26:163–168
  34. Sánchez M, Bruguera M, Bosch J, Rodés J, Ballesta F, Oliva R. Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. J Hepatol. 1998;29:725–728
  35. Sánchez M, Bruguera M, Quintero E, Barrio Y, Mazzara R, Rodés J, et al. Hereditary hemochromatosis in Spain. Genet Test. 2000;4:171–176
  36. Brissot P, Moirand R, Jouanolle AM, Guyader D, Le Gall JY, Deugnier Y, et al. A genotypic study of 217 unrelated probands diagnosed as “genetic hemochromatosis” on “classical” phenotypic criteria. J Hepatol. 1999;30:588–593
  37. Fabrega E, Castro B, Sanchez-Castro L, Benito A, Fernandez-Luna JL, Pons-Romero F. [The prevalence of the Cys282Tyr mutation in the hemochromatosis gene in Cantabria in patients diagnosed with hereditary hemochromatosis]. Med Clin (Barc). 1999;112:451–453
  38. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: a French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology. 1999;116:372–377
  39. Rossi E, Henderson S, Chin CY, Olynyk J, Beilby JP, Reed WD, et al. Genotyping as a diagnostic aid in genetic hemochromatosis. J Gastroenterol Hepatol. 1999;14:427–430
  40. de Villiers JN, Hillerman R, de Jong G, Langenhoven E, Rossouw H, Marx MP, et al. High prevalence of the Cys282Tyr HFE mutation facilitates an improved diagnostic service for hereditary hemochromatosis in South Africa. S Afr Med J. 1999;89:279–282
  41. Cardoso EM, Stål P, Hagen K, Cabeda JM, Esin S, de Sousa M, et al. HFE mutations in patients with hereditary hemochromatosis in Sweden. J Intern Med. 1998;243:203–208
  42. Gottschalk R, Seidl C, Loffler T, Seifried E, Hoelzer D, Kaltwasser JP. HFE codon 63/282 (H63D/C282Y) dimorphism in German patients with genetic hemochromatosis. Tissue Antigens. 1998;51:270–275
  43. Nielsen P, Carpinteiro S, Fischer R, Cabeda JM, Porto G, Gabbe EE. Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary hemochromatosis and in control subjects from Northern Germany. Br J Haematol. 1998;103:842–845
  44. Piperno A, Sampietro M, Pietrangelo A, Arosio C, Lupica L, Montosi G, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology. 1998;114:996–1002
  45. Aguilar Martinez P, Biron C, Blanc F, Masmejean C, Jeanjean P, Michel H, et al. Compound heterozygotes for hemochromatosis gene mutations: may they help to understand the pathophysiology of the disease?. Blood Cells Mol Dis. 1997;23:269–276
  46. Barton JC, Shih WW, Sawada-Hirai R, Acton RT, Harmon L, Rivers C, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis. 1997;23:135–145
  47. Borot N, Roth M, Malfroy L, Demangel C, Vinel JP, Pascal JP, et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics. 1997;45:320–324
  48. Carella M, D'Ambrosio L, Totaro A, Grifa A, Valentino MA, Piperno A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 1997;60:828–832
  49. Willis G, Jennings BA, Goodman E, Fellows IW, Wimperis JZ. A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England. Blood Cells Mol Dis. 1997;23:288–291
  50. Cukjati M, Vaupotic T, Rupreht R, Curin-Serbec V. Prevalence of H63D, S65C and C282Y hereditary hemochromatosis gene mutations in Slovenian population by an improved high-throughput genotyping assay. BMC Med Genet. 2007;8:69
  51. Brandhagen DJ, Fairbanks VF, Baldus WP, Smith CI, Kruckeberg KE, Schaid DJ, et al. Prevalence and clinical significance of HFE gene mutations in patients with iron overload. Am J Gastroenterol. 2000;95:2910–2914
  52. Murphy S, Curran MD, McDougall N, Callender ME, O'Brien CJ, Middleton D. High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish population—implications for hemochromatosis. Tissue Antigens. 1998;52:484–488
  53. Jouanolle AM, Fergelot P, Gandon G, Yaouanq J, Le Gall JY, David V. A candidate gene for hemochromatosis: frequency of the C282Y and H63D mutations. Hum Genet. 1997;100:544–547
  54. The UK Hemochromatosis Consortium. A simple genetic test identifies 90% of UK patients with hemochromatosis. Gut. 1997;41:841–844
  55. Ryan E, O'Keane C, Crowe J. Hemochromatosis in Ireland and HFE. Blood Cells Mol Dis. 1998;24:428–432
  56. Adams PC, Reboussin DM, Press RD, Barton JC, Acton RT, Moses GC, et al. Biological variability of transferrin saturation and unsaturated iron-binding capacity. Am J Med. 2007;120:999–997
  57. Aguilar-Martinez P, Schved JF, Brissot P. The evaluation of hyperferritinemia: an updated strategy based on advances in detecting genetic abnormalities. Am J Gastroenterol. 2005;100:1185–1194
  58. Hearnshaw S, Thompson NP, McGill A. The epidemiology of hyperferritinaemia. World J Gastroenterol. 2006;12:5866–5869
  59. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood. 2008;111:3373–3376
  60. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221–230
  61. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. Contribution of different HFE genotypes to iron overload disease: a pooled analysis. Genet Med. 2000;2:271–277
  62. Lester S, Bardy P, McCluskey J. HFE genotypes and hemochromatosis: quantifying the risks of disease. Tissue Antigens. 1999;54:282–284
  63. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood. 2004;103:2914–2919
  64. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology. 2007;46:1071–1080
  65. Smith GD, Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol. 2004;33:30–42

PII: S1047-2797(10)00127-4

doi: 10.1016/j.annepidem.2010.05.013

Annals of Epidemiology
Volume 21, Issue 1 , Pages 1-14 , January 2011

Article Tools

* Image Usage & Resolution